tiprankstipranks
Kailera Therapeutics, Inc. (KLRA)
NASDAQ:KLRA
US Market
KLRA
Kailera Therapeutics, Inc.
RESEARCH TOOLSreports

Kailera Therapeutics, Inc. (KLRA) Stock Forecast & Price Target

27 Followers
See the Price Targets and Ratings of:

KLRA Analyst Ratings

Strong Buy
5Ratings
Strong Buy
5 Buy
0 Hold
0 Sell
Based on 5 analysts giving stock ratings to
Kailera
Therapeutics, Inc.
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

KLRA Stock 12 Month Forecast

Average Price Target

$39.00
Based on 5 Wall Street analysts offering 12 month price targets for Kailera Therapeutics, Inc. in the last 3 months. The average price target is $39.00 with a high forecast of $48.00 and a low forecast of $30.00. The average price target represents a ― change from the last price of ―.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"22":"$22","49":"$49","28.75":"$28.8","35.5":"$35.5","42.25":"$42.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":48,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$48.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":39,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$39.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$30.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[22,28.75,35.5,42.25,49],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.18,25.08923076923077,26.998461538461537,28.907692307692308,30.816923076923075,32.72615384615385,34.635384615384616,36.54461538461538,38.45384615384616,40.363076923076925,42.27230769230769,44.181538461538466,46.09076923076923,{"y":48,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.18,24.396923076923077,25.613846153846154,26.83076923076923,28.04769230769231,29.264615384615386,30.481538461538463,31.698461538461537,32.91538461538462,34.13230769230769,35.34923076923077,36.566153846153846,37.78307692307692,{"y":39,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.18,23.704615384615384,24.229230769230767,24.753846153846155,25.27846153846154,25.803076923076922,26.327692307692306,26.85230769230769,27.376923076923077,27.90153846153846,28.426153846153845,28.950769230769232,29.475384615384613,{"y":30,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":26,"date":1748736000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":26,"date":1751328000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":26,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":26,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":26,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":26,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":26,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":26,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":26,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":26,"date":1772323200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":26,"date":1775001600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":25.15,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.18,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$48.00Average Price Target$39.00Lowest Price Target$30.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Jefferies Analyst forecast on KLRA
Roger Song
Jefferies
Jefferies
$48
Buy
―
Reiterated
05/28/26
Jefferies Sticks to Their Buy Rating for Kailera Therapeutics, Inc. (KLRA)
William Blair Analyst forecast on KLRA
Andy Hsieh
William Blair
William Blair
―
Buy
―
Reiterated
05/27/26
Analyst Initiates Buy on Kailera, Citing Diversified GLP‑1 Pipeline and Pivotal 2027 Obesity Data Catalysts
TD Cowen Analyst forecast on KLRA
Yaron Werber
TD Cowen
TD Cowen
―
Buy
―
Reiterated
05/26/26
TD Cowen Reaffirms Their Buy Rating on Kailera Therapeutics, Inc. (KLRA)
Evercore ISI Analyst forecast on KLRA
Umer Raffat
Evercore ISI
Evercore ISI
―
Buy
―
Initiated
05/12/26
Kailera Therapeutics initiated with an Outperform at Evercore ISIKailera Therapeutics initiated with an Outperform at Evercore ISI
J.P. Morgan Analyst forecast on KLRA
Hardik Parikh
J.P. Morgan
J.P. Morgan
$30
Buy
―
Initiated
05/12/26
Kailera Therapeutics initiated with an Overweight at JPMorganKailera Therapeutics initiated with an Overweight at JPMorgan
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Jefferies Analyst forecast on KLRA
Roger Song
Jefferies
Jefferies
$48
Buy
―
Reiterated
05/28/26
Jefferies Sticks to Their Buy Rating for Kailera Therapeutics, Inc. (KLRA)
William Blair Analyst forecast on KLRA
Andy Hsieh
William Blair
William Blair
―
Buy
―
Reiterated
05/27/26
Analyst Initiates Buy on Kailera, Citing Diversified GLP‑1 Pipeline and Pivotal 2027 Obesity Data Catalysts
TD Cowen Analyst forecast on KLRA
Yaron Werber
TD Cowen
TD Cowen
―
Buy
―
Reiterated
05/26/26
TD Cowen Reaffirms Their Buy Rating on Kailera Therapeutics, Inc. (KLRA)
Evercore ISI Analyst forecast on KLRA
Umer Raffat
Evercore ISI
Evercore ISI
―
Buy
―
Initiated
05/12/26
Kailera Therapeutics initiated with an Outperform at Evercore ISIKailera Therapeutics initiated with an Outperform at Evercore ISI
J.P. Morgan Analyst forecast on KLRA
Hardik Parikh
J.P. Morgan
J.P. Morgan
$30
Buy
―
Initiated
05/12/26
Kailera Therapeutics initiated with an Overweight at JPMorganKailera Therapeutics initiated with an Overweight at JPMorgan
Stocks with the Highest Top Analyst Consensus in the Sector
Find stocks in the sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Kailera Therapeutics, Inc.

3 Months
Roger SongJefferies
Success Rate
0/1 ratings generated profit
0%
Average Return
-12.30%
Copying Roger Song's trades and holding each position for 3 Months would result in 0.00% of your transactions generating a profit, with an average return of -12.30% per trade.
1 Year
Roger SongJefferies
Success Rate
0/1 ratings generated profit
0%
Average Return
-12.30%
Copying Roger Song's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -12.30% per trade.
2 Years
Roger SongJefferies
Success Rate
0/1 ratings generated profit
0%
Average Return
-12.30%
Copying Roger Song's trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -12.30% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

KLRA Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
0
0
0
4
4
Buy
0
0
0
6
6
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
0
0
0
10
10
In the current month, KLRA has received 10 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. KLRA average Analyst price target in the past 3 months is 39.00.
Each month's total comprises the sum of three months' worth of ratings.

KLRA Financial Forecast

KLRA Earnings Forecast

Next quarter’s earnings estimate for KLRA is -$0.78 with a range of -$1.03 to -$0.55. The previous quarter’s EPS was -$3.65K. KLRA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate ― of the time in the same period. In the last calendar year KLRA has its overall industry.
Next quarter’s earnings estimate for KLRA is -$0.78 with a range of -$1.03 to -$0.55. The previous quarter’s EPS was -$3.65K. KLRA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate ― of the time in the same period. In the last calendar year KLRA has its overall industry.
No data currently available

KLRA Sales Forecast

Next quarter’s sales forecast for KLRA is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. KLRA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates ― of the time in the same period. In the last calendar year KLRA has its overall industry.
Next quarter’s sales forecast for KLRA is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. KLRA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates ― of the time in the same period. In the last calendar year KLRA has its overall industry.

KLRA Stock Forecast FAQ

What is KLRA’s average 12-month price target, according to analysts?
Based on analyst ratings, Kailera Therapeutics, Inc.’s 12-month average price target is 39.00.
    What is KLRA’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for KLRA, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is KLRA a Buy, Sell or Hold?
        Kailera Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.
          What is Kailera Therapeutics, Inc.’s price target?
          The average price target for Kailera Therapeutics, Inc. is 39.00. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst price target is $48.00 ,the lowest forecast is $30.00. The average price target represents N/A Increase from the current price of N/A.
            What do analysts say about Kailera Therapeutics, Inc.?
            Kailera Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
              How can I buy shares of KLRA?
              Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.